Literature DB >> 31899820

Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab.

W Shehadeh1, O Sarig1, J Bar1, E Sprecher1,2, L Samuelov1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31899820     DOI： 10.1111/bjd.18855

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

Review 1.  Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.

Authors:  Tejas P Joshi; Hannah Y Wang; Prazwal Athukuri; Sarah Bohac; Morgan A Farr; Darien Hinson; Justin A Kahla; Nasim Khalfe; Dylan B McBee; Rachel Stroh; Nicole Walters; Vicky Ren
Journal:  Am J Clin Dermatol       Date:  2022-05-23       Impact factor: 6.233

Review 2.  Integrated Management Strategies for Epidermolysis Bullosa: Current Insights.

Authors:  Haseena Sait; Somya Srivastava; Deepti Saxena
Journal:  Int J Gen Med       Date:  2022-05-24

3.  Misdiagnosed dystrophic epidermolysis bullosa pruriginosa: A case report.

Authors:  Zi Wang; Yi Lin; Xing-Wu Duan; Hai-Yan Hang; Xia Zhang; Ling-Ling Li
Journal:  World J Clin Cases       Date:  2021-05-06       Impact factor: 1.337

Review 4.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

Review 5.  Challenges in Treating Genodermatoses: New Therapies at the Horizon.

Authors:  Marie-Anne Morren; Eric Legius; Fabienne Giuliano; Smail Hadj-Rabia; Daniel Hohl; Christine Bodemer
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

6.  Translational perspectives to treat Epidermolysis bullosa-Where do we stand?

Authors:  Christine Prodinger; Johann W Bauer; Martin Laimer
Journal:  Exp Dermatol       Date:  2020-11       Impact factor: 4.511
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.